全球热议HA前沿趋势 华熙生物的"中国方案"被高度评价 在2025世界透明质酸大会期间,华熙生物代表与国际透明质酸学会主席Dr. John Smith等权威学者就HA 的"非经典功能"展开深入探讨。华熙生物展示了"从基础研究到产业落地"的全链条技术研发体系,当展 示到300亿级分子数据库与AI辅助研发平台时,惊艳全场,现场专家学者给予高度评价:"华熙生物正在将 HA的生物医学价值,从'保湿因子'拓展至'万能分子'的技术升级,这种科研转化效率达到了全球最高水 平。" 近日,由国际透明质酸科学学会(International Society for Hyaluronan Sciences)主办的 HA2025大会在美国 伊利诺伊州召开。作为全球透明质酸领域的领军企业,华熙生物的研发团队携两项突破性科研成果受邀 参会,并与来自哈佛、剑桥等全球顶尖科研机构的专家、学者展开深度对话,以硬核科研实力与领先国际 的智造及产业转化能力,向世界展示了中国生物科技企业在透明质酸产业研发与产业转化和应用领域的 全球领先实力。 硬核成果亮相国际舞台 华熙生物定义HA产业新高度 华熙生物作为全球HA原料市场超过40%份额的领军企业,在 ...

转自：前瞻产业研究院 行业主要上市公司：华熙生物(688363.SH);昊海生科(688366.SH);爱美客(300896.SZ);创健医疗(873474.NQ);锦 波生物(832982.BJ);巨子生物(02367.HK)等 本文核心数据：毛利率;销售趋势;业务结构 1、销售毛利率：整体维持在70%以上，存在下降风险 随着医美行业的快速发展，以玻尿酸为代表的注射类项目，因其创口小、风险低以及恢复快等特点，深受医 美消费者追捧，占据轻医美项目主要市场。在此背景下，爱美客、华熙生物、昊海生科等企业凭借玻尿酸产 品的非凡表现，实现业绩快速增长，巅峰时期，毛利率高达90%，由此奠定了国内"玻尿酸三巨头"的市场地 位。国内"玻尿酸三巨头"毛利率整体维持在70%以上，2016至2024年，爱美客销售毛利率持续走高，2024年 销售毛利率达到惊人的95%，堪称医美中的茅台;华熙生物和昊海生科2016至2024年销售毛利率呈现逐步下 降趋势，2024年，华熙生物销售毛利率为74.07%，昊海生科售毛利率为69.52%，玻尿酸市场竞争的加剧和 市场红利的逐渐消退，使得医美企业正面临着新的挑战。 2、昊海生科："投资并购" ...

6 月 23 日晚，巨子生物在官方微信公众号发布关于重组胶原蛋白产品有关问题的说明，明晰 了自查结果和下一步措施。 巨子生物承认： " 我公司现有的质量标准、检测方法和标签标识在某些方面已逐渐显现出其 局限性，难以完全适配行业发展与技术进步的高标准和高要求。 " 【导读】巨子生物回应重组胶原蛋白产品问题 中国基金报记者 赵心怡 两大医美巨头 —— 巨子生物和华熙生物之间的纷争迎来 " 最终章 " 。（此前详情可参考报 道《 价值研究所｜撕扯、炒作？美妆巨头成分 " 罗生门 " 》） 6 月 24 日开盘，巨子生物股价一度大涨超 7% 。 巨子生物：检测标准和方法存在局限性 从现有行业标准来看，发布和实施日期基本集中在近 5 年，目前最新的一版是 2025 年发布 的医药行业标准 YY/T 1947-2025 《重组胶原蛋白敷料》，将于 2026 年 3 月实施。 巨子生物表示： " 随着重组胶原蛋白产业的快速发展，以及消费者对产品质量要求的日益增 长，我公司现有的质量标准、检测方法和标签标识在某些方面已逐渐显现出其局限性，难以 完全适配行业发展与技术进步的高标准和高要求，需要不断优化迭代。 " 对于未来发展， ...

华熙生物否认针对竞争对手的"商战"传言，反对成分命名上的"名称游戏"。 近期，医美行业中围绕"重组胶原蛋白"的探讨，已从学术概念之争演变为医美龙头企业的股价剧烈波 动，引发广泛关注。 这场行业论战始于华熙生物对胶原蛋白领域的质疑，随后美妆博主"大嘴博士"郝宇对巨子生物提出技术 质疑，使争议进一步发酵。 数据显示，5月24日至6月18日期间，市场反应呈现两极分化：华熙生物股价累计上涨23.65%，而主打 重组胶原蛋白概念的巨子生物同期跌幅超过31%。 但从市值来看，截至6月18日收盘，巨子生物市值约514亿元人民币，而华熙生物市值245亿元，仍不足 前者一半。 针对近期争议，华熙生物在回应媒体采访时强调，公司坚决反对在成分命名上玩"名称游戏"，并否认相 关举措存在"商战"动机。 反对"名称游戏" 华熙生物指出，资本市场概念切换导致对透明质酸和重组胶原蛋白的认知出现偏差，这不仅影响了企业 经营环境，也给相关企业带来资源错配风险。 华熙生物表示，其坚决反对成分"名称游戏"。 在关于重组胶原蛋白添加问题的讨论中，华熙生物认为，国货品牌可信度不能建立在学术概念滥用、利 用标准疏漏和水军引导消费者误判的基础上，否则将扭曲 ...

Core Viewpoint - ECM (Extra Cellular Matrix) has been identified as a significant marker of aging, leading to increased focus and competition among beauty brands in anti-aging research and product development [1][3][10]. Group 1: Industry Trends - The recognition of ECM as an aging marker has prompted major beauty companies to rapidly advance their research and product offerings related to ECM [6][9]. - Companies like Huaxi and Marubi are expanding their research to include all major ECM proteins, indicating a shift towards a more comprehensive understanding of skin aging [6][9]. - The launch of innovative products, such as Huaxi's "润百颜·玻玻" and Shiseido's MicroClick Concentrate, highlights the industry's commitment to integrating ECM research into practical applications [6][9][10]. Group 2: Key Research Findings - ECM plays a crucial role in maintaining mitochondrial homeostasis, cellular aging, and stem cell depletion, making it a pivotal focus in anti-aging research [3][10]. - The dynamic network of ECM, composed of hyaluronic acid, collagen, and elastin, is essential for skin elasticity and vitality, with its degradation being a primary mechanism of skin aging [10][14][19]. - Research indicates that a healthy ECM can rejuvenate aging skin, restoring its appearance and function [17][19]. Group 3: Competitive Landscape - Major beauty brands are leveraging their existing research on key ingredients like hyaluronic acid and collagen to enhance their ECM-focused anti-aging strategies [24][26]. - The integration of ECM research is seen as a way to unify various scientific advancements within the beauty industry, creating a more holistic approach to skin aging [24][25]. - The collaboration between medical aesthetics and beauty sectors is expected to accelerate the development of innovative anti-aging solutions based on ECM [26][27]. Group 4: Future Opportunities - The potential applications of ECM research extend beyond facial care, with implications for hair follicle regeneration and other areas of dermatology [22][27]. - The beauty industry is positioned to explore new avenues in regenerative medicine and tissue engineering, utilizing ECM's properties to enhance skincare products [27][28]. - ECM is viewed as a "new gold mine" for the beauty industry, offering significant opportunities for innovation and market growth [27][28].

Core Insights - The Ministry of Industry and Information Technology and the National Development and Reform Commission have initiated a program to cultivate over 20 pilot platforms for biomanufacturing by 2027, aiming to facilitate industrial scale-up [1] - Significant technological breakthroughs and industrial layouts are emerging in the biomanufacturing sector, with advancements in areas such as polysulfone plastic recycling and wool sterol synthesis [1] - The synergy between policy support and industrial development is accelerating the transition of biomanufacturing from laboratory research to large-scale industrialization, showcasing a vibrant development chain of "technological breakthroughs - policy support - capital influx" [1] Industry Developments - Synthetic biology is reshaping production models in biomanufacturing, enabling tasks that traditional biotechnologies cannot achieve, while also providing more efficient and environmentally friendly biosynthesis solutions [1] - Companies like Huaxi Biological and Yikole are extending their capabilities in synthetic biology, with Huaxi focusing on the supply chain of hyaluronic acid and Yikole leveraging CRISPR-Cas9 technology for precise gene editing [2][3] - The integration of synthetic biology with traditional industries is seen as a means to enhance productivity and create new growth opportunities, rather than a conflict [4] Technological Innovations - Companies are developing comprehensive systems in synthetic biology, focusing on tool, platform, and product integration, with significant advancements in production efficiency [3] - AI is playing a crucial role in enhancing research efficiency in synthetic biology, with companies establishing AI teams to optimize data collection and algorithm development [7] - The use of AI in the design and testing phases of synthetic biology is expected to significantly reduce research timelines and costs, improving overall productivity [7] Market Trends - The biomanufacturing industry is experiencing a wave of policy support, with various local governments implementing initiatives to promote the industrialization of synthetic biology [8] - The market for biomanufacturing in China is projected to approach 1.8 trillion yuan by 2030, indicating substantial growth potential [8] - Recent financing trends show an acceleration in investments in domestic synthetic biology companies, with nearly a hundred firms securing new funding at the beginning of 2025 [8] Future Outlook - The synthetic biology sector is anticipated to undergo rapid technological iterations and deeper application expansions in the next 3-5 years, driven by AI advancements [9] - Companies are encouraged to focus on quality improvement and original design rather than mere scale expansion, to avoid resource wastage and industry chaos [9] - The industry is expected to face dual challenges in technology transfer and industrialization, particularly in constructing microbial cell factories and overcoming engineering challenges in fermentation and purification [10]

近日，华熙生物公众号发布《关于透明质酸和重组胶原蛋白的传言与真相》。当中谈到，资本市场概念 切换带来的关于透明质酸和重组胶原蛋白的误导性认知，已经远远偏离了科学和产业发展的基本面。如 果不加以纠正，不但会影响到华熙生物等一大批企业的经营环境，也会给以重组胶原蛋白为经营概念的 企业带来资源错配和风险，因为任何从业者都不可能绕开生物学的基本规律和产业的基本规律走得太 远。 近几年基于基因工程表达的重组胶原蛋白获得了快速发展，华熙生物也在从事相关的研究和产业转化， 华熙生物的重组胶原蛋白原料已初步经过市场验证，正持续供应给其他行业企业。但有几个基本的事实 一直在提醒我们把握好"先行先试"和"全球领先"之间的表述差异：首先，"重组的"胶原蛋白只是胶原蛋 白研究和产业转化当中很小的一个分支，整个蛋白质组学研究，包括胶原蛋白研究和转化的制高点依然 掌握在生命科学研究机构和医药企业手中，并不掌握在医美或化妆品公司，资本市场不能不顾这些基本 事实去引导对"全球领先"的错误预期。 其次，以基于重组胶原蛋白的医美三类械证书为例，国际上还没有相关的准入批复，这当然说明我们在 先行探索，另一方面也说明我们需要更长的实践观察周期。 而 ...

对此，华熙生物表示根据我们的竞争情报分析，这一传言是基于一套标准的母内容模板，已经通过网络 水军散布了数年时间，并与不负责任的所谓"研报"形成了共振。一旦华熙生物有什么风吹草动，都会被 归结为"竞争失败"，归结为"透明质酸过时，重组胶原蛋白兴起"。但这些并不符合经营数据反映的真 相。 6月14日，华熙生物今日晚间发文《关于透明质酸和重组胶原蛋白的传言与真相》，再度回应近期与巨 子生物之间的风波。 有传言说华熙生物上述举措是基于"商战"，根本原因是华熙生物的透明质酸业务承压、重组胶原蛋白无 法与对手竞争，导致了业绩大幅下滑？ 华熙业绩下滑的主要原因其实是消费品业务下滑和一次性为了夯实资产质量而进行的资产减值带来的亏 损。如果没有这些亏损，华熙生物是一个盈利能力卓越的公司。另一方面，从竞争大图景看，最近一两 年业绩良好的公司也并非是重组胶原蛋白赛道兴起的原因，如一些电商运营能力强的企业一直都在领跑 护肤品业务的增长，而这一业务是基于复合配方而非单一成分。重组胶原这个赛道也有很多企业在亏 损，所以不能仅归因于某一赛道的兴起，还是因为这个领域有些C端企业一直保持着强运营的基因，在 这个问题上，我们跟市场上的传言有完全 ...

6月14日，华熙生物今日晚间发文《关于透明质酸和重组胶原蛋白的传言与真相》，再度回应近期风 波。 5月17日，华熙生物发布了"概念总在重演，科技永远向前"一文，质疑券商热捧重组胶原蛋白并非基于 科学逻辑。随后，市场出现了针对重组胶原蛋白产品学术概念及有效添加的质疑，华熙生物随后也表达 了支持这类讨论，提出反对成分"名称游戏"，这一系列举措的根本目的是什么？ 最后，从产业角度，华熙生物表示，"还没有看到这一领域有像透明质酸那样的成熟并高速发展的国际 市场，2024年中国的透明质酸出口量达到了161吨，其中医药级高端透明质酸出口了11.8吨。而同期， 重组胶原蛋白的出口量却不到0.02吨。所以，'重组胶原蛋白'正在取代'透明质酸'的传言在全球市场没 有原料消耗的数据支持。即便在资本概念切换中期待很高的国内市场，这种热度也是缺乏真实数据支持 的，我们非常了解市场上以重组胶原蛋白为概念的品牌采购了多少华熙生物的透明质酸和其他活性物， 也非常清楚其交叉检测的真实添加数据。" 责任编辑：陈钰嘉 华熙生物强调，近几年基于基因工程表达的重组胶原蛋白获得了快速发展，华熙生物也在从事相关的研 究和产业转化，华熙生物的重组胶原蛋白 ...

Core Viewpoint - The controversy surrounding the collagen product "Kefumei" and its alleged false claims has led to significant media attention and a public dispute between two major players in the beauty and medical aesthetics industry, Juzhibio and Huaxi Biological. Group 1: Allegations and Responses - The beauty blogger "Dr. Big Mouth" raised concerns about the collagen content in "Kefumei" products, claiming it was only 0.02%, below the regulatory threshold of 0.1% [5] - Juzhibio, the parent company of "Kefumei," denied these allegations, asserting that their internal tests showed collagen content exceeding 0.1%, with third-party tests indicating levels between 0.2% and 0.22% [8] - The blogger's videos related to Juzhibio were removed from social media platforms, which he attributed to malicious reporting rather than voluntary deletion [1] Group 2: Industry Dynamics - The dispute is seen as a competitive clash between Juzhibio and Huaxi Biological, with the latter supporting the blogger's claims and hinting at a potential "business war" [8] - Juzhibio's market capitalization is reported to be over twice that of Huaxi Biological, despite similar performance levels, indicating a market preference for Juzhibio's collagen products [8] - Huaxi Biological had previously attempted to enter the collagen market through acquisitions, indicating a strategic interest in this segment [9] Group 3: Market Impact - Following the public dispute, both Juzhibio and Huaxi Biological experienced stock price declines, with Juzhibio opening at 59.8 HKD per share and Huaxi Biological at 54.34 CNY per share [11]